Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent must be obtained from the subject or health care proxy before any assessment is performed.~* Adults (male and female) aged 65 years and over.~* Residing in a nursing home in which one or more residents or staff has developed laboratory-confirmed symptomatic COVID-19 infection at the time of randomization~Exclusion Criteria:~Subjects will not be eligible if they meet any of the following criteria:~* Any subject who is a current smoker or has a ≥ 10 pack year smoking history.~* Subjects with a medical history of chronic obstructive pulmonary disease (COPD).~* Subjects who are in hospice or receiving comfort care only.~* Subjects who have symptomatic laboratory-confirmed COVID-19 at the time of screening or randomization.~* Subjects with current evidence of an unstable medical disorder including an unstable respiratory disorder, gastrointestinal disorder (including Child-Pugh class B and C hepatic impairment), renal disorder (including subjects with an estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73m2), or hematologic disorder (including active leukemia).~* Subjects receiving immunosuppressive therapy including chronic use of prednisone \>10 mg daily (however, inhaled corticosteroids and acute use of higher doses of prednisone to treat conditions such as exacerbation of asthma or other acute conditions are allowed).~* Subjects with an immunodeficiency disease, including a positive human immunodeficiency virus (HIV) test result.~* Sexually active males with a partner of child-bearing potential

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 mg daily RTB101 (Type: EXPERIMENTAL): TORC1 inhibitor
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).